1. HIV 2015-2016: New Agents, New Strategies

4. Learning Objectives

5. EARLY VS DEFERRED ART The Case is Made

6. Should Early-Stage Asymptomatic HIV Patients Receive ART
Should Early-Stage Asymptomatic HIV Patients Receive ART? The INSIGHT START Study

7. The CD4+ Cell Count As a Measure of Immune Deficiency in HIV+ Patients How Good Is It?

8. Immediate vs Deferred ART and Isoniazid Preventive Therapy TEMPRANO Studya

9. Global Agreement on EARLY ART Initiation

11. INSTIs vs Boosted PIs ACTG 5257 Study

12. The Triumph of INSTIs Over Boosted PIs ACTG 5257 Study

13. INSTI vs Boosted PI SINGLE Study (N=833)

14. Dolutegravir Superior to Boosted Darunavir FLAMINGO Study (N=484)

15. INSTIs vs Boosted PIs in Treatment-Naïve Patients Summary of Clinical Evidence

17. Interesting But… Limitations of PADDLE

18. New Formulation of Tenofovir TAF

19. TAF Replaces TDF in Fixed-Dose Pill

20. Switching Virologically-Suppressed Patients From TDF- to TAF-Based Regimen Improved Virologic Outcomes at 48 Wk (N=1433)

21. Significant Improvement in BMD and Renal Function With Switch to TAF

22. Switching From TDF to TAF Improves Renal Function at 48 Wk in Patients With Renal Impairment

23. Fixed-Dose Tablet: DTG/ABC/3TC STRIIVING Study

24. Virologic Outcomes Maintained in Patients Switched to DTG/ABC/3TC STRIIVING Study

25. Possible Reasons for Discontinuations in STRIIVING Study

27. Dolutegravir Monotherapy Switch Study Suggests Benefit for Select Patients

28. Dolutegravir Monotherapy Proceed With Caution

29. EFFICACY OF ART IN HIV-INFECTED WOMEN

30. First All-Women Study of ART Efficacy WAVES Study

31. WAVES 48-Week Data

32. Why Did Results Differ From a Similar Study of Mostly Mena?

33. Why Is It Difficult to Recruit Women Into Clinical Trials?

35. Daclatasvir/Sofosbuvir for 8 vs 12 Wk to Treat HCV in HIV/HCV-Coinfected Patients ALLY-2 Study

36. Efficacy of Treating HCV With Ledipasvir/ Sofosbuvir for 12 Wk in HIV/HCV-Coinfected Patients ION-4 Study

37. New Combination of Sofosbuvir/ Velpatasvir Achieves High HCV SVR Rates Across HCV Genotypes ASTRAL-1 Study

38. Grazoprevir/Elbasvir: High HCV Cure Rates in HIV/HCV-Coinfected Patients C-EDGE CO-INFECTION

39. Treatment of HIV/HCV Coinfection Looking Forward

40. LONG-ACTING FORMULATIONS

41. Switch To a Long-Acting Nanoparticle Emulsion Formulation of Cabotegravir + Rilpivirine: 32-Wk Results LATTE-2 Studya,b

42. Potential Benefits of Long-Acting Injectable Agents

43. Summary

44. Abbreviations

45. Abbreviations (cont)

46. Abbreviations (cont)

47. Abbreviations (cont)